Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ginkgo Bioworks Holdings, Inc.DNA · Entity 5530 | Director · See remarks | July 28, 2026 | July 30, 2026 |
| SomaLogic, Inc.CMII · Entity 95310 | Director | February 22, 2021 | February 22, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ginkgo Bioworks Holdings, Inc.
Report date July 28, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 74,258 |
Reported balance
After 2026-07-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-28 · Grant · Acquired 74,258 · Balance 74,258 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest as follows: 75% on October 16, 2026 and 25% on January 21, 2027. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 309,467 |
Reported balance
After 2026-07-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-28 · Grant · Acquired 309,467 · Balance 309,467 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest in equal quarterly installments over the next 12 quarters, with the first vesting to occur on October 16, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest as follows: 75% on October 16, 2026 and 25% on January 21, 2027.
F3: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest in equal quarterly installments over the next 12 quarters, with the first vesting to occur on October 16, 2026.
SomaLogic, Inc.
Report date February 22, 2021 · Filed February 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B common stockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-02-22 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder as described under the heading "Description of Securities--Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-252626) (the "Registration Statement"), on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder as described under the heading "Description of Securities--Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-252626) (the "Registration Statement"), on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2023 Filed Feb 9, 2023 21:35 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.87 | $187,200.00 |
DisclosureSEC source: 0001127602-23-004242 · form4.xml · nonDerivative · entry 3 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,194,680 F2 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.80 to $1.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| February 08, 2023 Filed Feb 9, 2023 21:35 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 128,864 | $1.88 | $242,650.91 |
DisclosureSEC source: 0001127602-23-004242 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,294,680 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 21:35 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 151,769 | $1.96 | $297,619.01 |
DisclosureSEC source: 0001127602-23-004242 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,423,544 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 21:43 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 157,790 | $1.98 | $312,897.57 |
DisclosureSEC source: 0001127602-23-003809 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,575,313 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 21:43 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 156,383 | $2.13 | $332,626.64 |
DisclosureSEC source: 0001127602-23-003809 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,733,103 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:10 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $2.17 | $216,790.00 |
DisclosureSEC source: 0001127602-23-003383 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,889,486 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.06 to $2.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 22:20 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 154,910 | $1.91 | $296,187.92 |
DisclosureSEC source: 0001127602-23-003174 · form4.xml · nonDerivative · entry 3 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,989,486 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 22:20 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.93 | $192,880.00 |
DisclosureSEC source: 0001127602-23-003174 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,144,396 F2 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.87 to $2.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 22:20 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 149,554 | $1.85 | $276,375.79 |
DisclosureSEC source: 0001127602-23-003174 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,244,396 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| January 30, 2023 Filed Jan 31, 2023 22:01 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 156,012 | $1.89 | $294,706.67 |
DisclosureSEC source: 0001127602-23-002757 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,393,950 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 22:01 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 145,907 | $1.82 | $265,842.55 |
DisclosureSEC source: 0001127602-23-002757 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,549,962 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 22:15 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.76 | $176,210.00 |
DisclosureSEC source: 0001127602-23-002471 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,695,869 F2 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.72 to $1.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 22:15 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 151,171 | $1.77 | $267,270.33 |
DisclosureSEC source: 0001127602-23-002471 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,795,869 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| January 25, 2023 Filed Jan 26, 2023 22:07 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 158,748 | $1.73 | $274,951.54 |
DisclosureSEC source: 0001127602-23-002318 · form4.xml · nonDerivative · entry 3 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,947,040 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| January 25, 2023 Filed Jan 26, 2023 22:07 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.73 | $172,990.00 |
DisclosureSEC source: 0001127602-23-002318 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,105,788 F2 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 22:07 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 153,994 | $1.82 | $279,499.11 |
DisclosureSEC source: 0001127602-23-002318 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,205,788 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| January 23, 2023 Filed Jan 24, 2023 22:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 143,807 | $1.75 | $252,093.67 |
DisclosureSEC source: 0001127602-23-002139 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,359,782 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 22:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 152,205 | $1.67 | $253,573.53 |
DisclosureSEC source: 0001127602-23-002139 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,503,589 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| January 19, 2023 Filed Jan 20, 2023 22:18 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 162,193 | $1.71 | $277,998.80 |
DisclosureSEC source: 0001127602-23-001968 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,655,794 F3 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| January 19, 2023 Filed Jan 20, 2023 22:18 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.69 | $168,630.00 |
DisclosureSEC source: 0001127602-23-001968 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,817,987 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.64 to $1.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 18, 2023 Filed Jan 19, 2023 23:19 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 154,796 | $1.95 | $302,161.79 |
DisclosureSEC source: 0001127602-23-001857 · form4.xml · nonDerivative · entry 3 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,917,987 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| January 18, 2023 Filed Jan 19, 2023 23:19 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.92 | $192,100.00 |
DisclosureSEC source: 0001127602-23-001857 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,072,783 F2 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.81 to $2.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 23:19 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 151,531 | $1.86 | $282,453.78 |
DisclosureSEC source: 0001127602-23-001857 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,172,783 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 22:59 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 157,627 | $1.77 | $279,472.67 |
DisclosureSEC source: 0001127602-23-001485 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,324,314 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| January 12, 2023 Filed Jan 13, 2023 22:11 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.74 | $173,960.00 |
DisclosureSEC source: 0001127602-23-001421 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,481,941 F2 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.645 to $1.855, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 12, 2023 Filed Jan 13, 2023 22:11 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 152,693 | $1.69 | $258,203.86 |
DisclosureSEC source: 0001127602-23-001421 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,581,941 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| January 11, 2023 Filed Jan 12, 2023 22:16 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 146,449 | $1.60 | $233,879.05 |
DisclosureSEC source: 0001127602-23-001350 · form4.xml · nonDerivative · entry 3 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,734,634 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| January 11, 2023 Filed Jan 12, 2023 22:16 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.64 | $164,040.00 |
DisclosureSEC source: 0001127602-23-001350 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,881,083 F2 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.53 to $1.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 22:16 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 157,798 | $1.50 | $236,854.80 |
DisclosureSEC source: 0001127602-23-001350 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,981,083 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| January 09, 2023 Filed Jan 10, 2023 22:17 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 152,159 | $1.52 | $230,825.20 |
DisclosureSEC source: 0001127602-23-001237 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,138,881 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 22:17 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 152,094 | $1.49 | $226,772.15 |
DisclosureSEC source: 0001127602-23-001237 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,291,040 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 23:23 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 144,521 | $1.53 | $221,550.69 |
DisclosureSEC source: 0001127602-23-001104 · form4.xml · nonDerivative · entry 3 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,443,134 F4 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 23:23 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.54 | $154,250.00 |
DisclosureSEC source: 0001127602-23-001104 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,587,655 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.50 to $1.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 23:23 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.55 | $155,330.00 |
DisclosureSEC source: 0001127602-23-001104 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,687,655 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.455 to $1.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 23, 2022 Filed Dec 27, 2022 22:13 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 203,349 | $1.64 | $334,305.76 |
DisclosureSEC source: 0001127602-22-028296 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,787,655 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| December 22, 2022 Filed Dec 23, 2022 21:21 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 209,385 | $1.66 | $348,207.26 |
DisclosureSEC source: 0001127602-22-028247 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,991,004 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| December 21, 2022 Filed Dec 23, 2022 21:21 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 193,211 | $1.70 | $328,458.70 |
DisclosureSEC source: 0001127602-22-028247 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,200,389 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| December 20, 2022 Filed Dec 21, 2022 22:15 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 408,767 | $1.66 | $676,509.39 |
DisclosureSEC source: 0001127602-22-028090 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,393,600 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 22:15 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 206,449 | $1.67 | $344,356.93 |
DisclosureSEC source: 0001127602-22-028090 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,802,367 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 02:04 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 101,426 | $1.60 | $162,180.17 |
DisclosureSEC source: 0001127602-22-027929 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,008,816 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| December 15, 2022 Filed Dec 20, 2022 02:04 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 103,547 | $1.61 | $167,124.86 |
DisclosureSEC source: 0001127602-22-027929 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,110,242 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| December 14, 2022 Filed Dec 15, 2022 22:15 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 102,345 | $1.69 | $173,167.74 |
DisclosureSEC source: 0001127602-22-027580 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,213,789 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 22:15 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 98,934 | $1.89 | $187,084.19 |
DisclosureSEC source: 0001127602-22-027580 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,316,134 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| December 12, 2022 Filed Dec 13, 2022 22:16 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 98,606 | $1.84 | $181,040.62 |
DisclosureSEC source: 0001127602-22-027408 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,415,068 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 22:16 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 97,554 | $1.84 | $179,109.14 |
DisclosureSEC source: 0001127602-22-027408 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,513,674 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 22:15 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 97,204 | $1.79 | $174,092.36 |
DisclosureSEC source: 0001127602-22-027221 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,611,228 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 22:15 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,909 | $1.69 | $170,132.57 |
DisclosureSEC source: 0001127602-22-027221 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,708,432 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| December 06, 2022 Filed Dec 7, 2022 22:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 103,392 | $1.73 | $179,074.94 |
DisclosureSEC source: 0000899243-22-037899 · doc4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,809,341 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 22:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 106,006 | $1.87 | $198,019.21 |
DisclosureSEC source: 0000899243-22-037899 · doc4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,912,733 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| December 01, 2022 Filed Dec 6, 2022 02:14 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,429 | $1.97 | $198,045.99 |
DisclosureSEC source: 0000899243-22-037730 · doc4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,018,739 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.